Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics, an LFB company, announced positive preliminary results of a key dose ranging study, which demonstrates that LR769, a novel recombinant form of human Factor VIIa (rhFVIIa), is biologically active and well tolerated in patients with congenital hemophilia A or B at the three dosages tested.
Help employers find you! Check out all the jobs and post your resume.
